Tags : INMARK Study

Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study

Vartika Singh July 19, 2019

Shots: The INMARK study involves assessing of Ofev (nintedanib) vs PBO in 347 patients with IPF for 12 wks., followed by an open label period of 40 wks. The study […]readmore

Tags : INMARK Study

Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : INMARK Study

﻿Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study